Endo rating altered to buy/high risk by Citigroup

Endo Pharmaceuticals Holdings, Inc. was given an altered rating of buy/high risk from buy/medium risk, with a target price of $32, by Citigroup Investment Research analyst Andrew Swanson. The Court of Appeals has reconsidered its decision regarding the validity of Purdue's Oxycontin patents and has remanded the case to the district court. Shares of the Chadds Ford, Pa., pharmaceutical company were down $1.33, or 4.98%, at $25.39 on volume of 3,042,155 shares versus the three-month running average of 1,410,320 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.